Hypoxia-activated prodrugs (HAPs) present a conceptually elegant approach to not only overcome, but better yet, exploit intra-tumoural hypoxia. Despite being successful in vitro and in vivo, HAPs are yet to achieve successful results in clinical settings. It has been hypothesised that this lack of clinical success can, in part, be explained by the insufficiently stringent clinical screening selection of determining which tumours are suitable for HAP treatments [1].
Introduction
Oxygen concentrations vary across solid tumours and, although tumours present with high diversity across patients [2] , hypoxic regions are prevalent tumour features [3, 4, 5, 6, 7, 8, 9, 10, 11] commonly provoked by inadequate oxygen supply and high tumour growth rates [12] . Hypoxia significantly impacts tumour dynamics, treatment responses and, by extension, clinical outcomes [13, 6, 9] . Hypoxia may alter cellular expressions of genomes, proteins and epigenetic traits [12] , and such hypoxia-induced alterations may cause hypoxic cancer cells to be more resistant to apoptosis [14] . Hypoxia may also alter the metabolism of cells [14] , promote angiogenesis by activating associated genes [15] and upregulate efflux systems [16] . Thus hypoxia both protects and progresses solid tumours [14, 13] . Accordingly, severe tumour hypoxia is associated with tumours that are difficult to treat and, by extension, poor prognoses for patients [12, 7] . It is well established that hypoxic regions in solid tumours express reduced sensitivity to radiotherapy and a plethora of chemotherapeutic drugs [12, 15, 17, 14, 6, 7, 18, 8, 9, 19, 11] . Hypoxic cancer cells in a solid tumour are naturally located far away from active oxygen sources, i.e. blood vessels [7] , and therefore drug molecules that are of large size or tightly bound to cell components may not reach hypoxic tumour cells at all [15] . Moreover, genes associated with chemo-resistance may be upregulated by hypoxia [1] . Hypoxia is also regarded to be one of the main factors contributing to radiotherapy failure [15] . Radiation-induced DNA damage, especially in the form of double strand breaks, is more easily self-repaired by the cell under hypoxic conditions [20] .
Due to their severe impact on conventional anticancer therapies, such as chemotherapy and radiotherapy, hypoxic cancer cells, and their central mediators [12] , have for the last decades been considered to be important treatment-targets [15, 2] . In treatment scenarios in which rapid tumour re-oxygenation does not occur, hypoxic tumour regions can, instead, be more directly targeted. Multiple ways to handle tumour hypoxia have been explored. One approach to combat intratumoural hypoxia is to increase the tumour oxygenation as part of a neoadjuvant treatment [1] . A second approach to overcome hypoxia is to selectively target hypoxic cancer cells only for treatment-sensitising or eradication [4] . A third and conceptually elegant approach to not only overcome, but better yet, exploit intratumoural hypoxia is realised by hypoxia-activated prodrugs (HAPs) [15] . HAPs are bioreductive prodrugs that reduce, and thus convert, into cytotoxic agents upon reaching hypoxic (tumour) regions [14, 19] . Theoretically, they act as Trojan horses, ideally being essentially harmless until they are converted into warheads in target regions, i.e. hypoxic (tumour) cells. The tumour-targeting ability of HAPs is based on the premise that oxygen concentrations in hypoxic tumour regions reach exceptionally low levels, and that such low oxygen levels are much more prevalent in tumours, than in the body tissue that locally surrounds the tumours [14] . Indeed physoxia, that is the term commonly used to describe oxygen levels found in several types of normal tissue, ranges between 10 and 80 mmHg, and a cancer cell is commonly classified as hypoxic if it has a partial pressure of oxygen (pO 2 ) value of 10 mmHg or less [5] . Solid tumours commonly display regions that are even more hypoxic, where pO 2 values may drop below 5 mmHg [5] . Consequently, HAPs theoretically constitute a means to effectively target hypoxic tumour cells. This also means that toxic drug effects can be localised to tumours, and that the remaining host system can in great part be spared from harmful toxicity causing unwanted side effects.
HAPs transform into activated drugs (AHAPs) via reductive metabolism [15, 3] in sufficiently hypoxic environments, and the AHAPs can achieve cytotoxic effects in cells [21] . Freely available molecular oxygen may inhibit this bioreduction, and thus HAPs remain (for the most part) more intact, and by extension less toxic, in well-oxygenated environments [14] . Once activated, certain AHAPs may diffuse into their local surroundings. Thus, via bystander effects, for certain HAP drugs, AHAPs may infer damage to cells in which the HAP-to-AHAP bioreduction did not occur. However, a few recent studies dispute the impact of these bystander effects on the overall treatment outcome [22] . In the mathematical model described in this study, the dispersion of HAPs and AHAPs obey mechanistic diffusion equations, and the reach of AHAPs can easily be modified by altering coefficients in the AHAP diffusion equation. Thus the influence of bystander effects on the treatment outcome is allowed to range from negligable to highly influential in our mathematical model.
Multiple HAPs have been evaluated for their clinical potential, both as monotherapies and as part of combination therapies [12, 8] . Class I HAPs are activated in moderately hypoxic environments whilst Class II HAPs require more severe hypoxia to undergo the HAP to AHAP bioreduction [23] . One such Class II HAP is evofosfamide, or TH-302, which has been tested in clinical Phase I-III trials [12, 1] . TH-302 bioreduces to its activated form, bromo-isophosphoramide mustard (Br-IPM), in hypoxic tumour regions, and Br-IPM is a DNA-crosslinking agent [22] . Multiple in vitro and in vivo studies have validated this drug's preclincal success and, by extension, its clinical feasibility [13, 24, 25, 26, 6, 7, 18, 27, 9, 21, 10, 28] . Multimodality treatment strategies combining HAPs, particularly Class II HAPs, with ionising radiation (IR) may be particularly promising [29, 8, 9, 27, 28] as the two therapies conceptually complement each other: HAPs target hypoxic tumour regions whilst radiotherapy is most effective against well oxygenated tumour regions. Thus, in principal, HAP-IR combination treatments have the ability to produce multifaceted attacks on tumours.
Despite HAPs being conceptually promising and successful in laboratories, this success has not yet been mirrored in clinical trials [12, 2, 1] . It is hypothesised that this unsuccessful Benchto-Bedside translation is partly due to an insufficiently stringent clinical screening practice of selecting tumours that are suitable for HAP treatments [1] . It is likely that some of the tumours enrolled in clinical trials have been insufficiently hypoxic to benefit from treatment plans involving HAPs [2] . To investigate this hypothesis, we here propose a mathematical modelling angle to simulate how spatio-temporal tumour features may impact HAP efficacy and how scheduling influences the outcome of multimodality HAP-IR treatments. Today, mathematical modelling constitutes an indispensable complement to traditional cancer research. Models provide an opportunity to study biological phenomena in silico that may not be empirically observable and, moreover, in silico experiments are fast and cheap to run, easy to reproduce and not directly associated with any ethical concerns. Previous mathematical studies have already contributed to the overall understanding of HAPs, quantified key mechanisms associated to them and illustrated their clinical feasibility. Foehrenbacher et al. [30] have deployed a Green's function method, in customised form, and pharmacokinetic/pharmacodynamic (PK/PD) modelling to quantify anticancer bystander effects elicited by the HAP PR-104 in a simulated, three-dimensional tumour comprising a microvascular network. Another concurrent article used similar mathematical concepts to compare Class I HAPs to Class II HAPs and, furthermore, to determine optimal properties for Class II HAPs [23] . Lindsay et al. [31] developed a stochastic model to study monotherapies and combination therapies involving HAPs, specifically TH-302, and erlotinib. Amongst other findings, they concluded that a combination therapy of the two drugs impedes the uprising of drug resistance. Since HAPs bioreduce to activated form under hypoxic conditions it follows that AHAP activity increases with intratumoural hypoxia. Accordingly, a previous study by Wojtkowiak et al. [32] conceptually validated the strategy of amplifying TH-302 activity by deliberately exacerbating intratumoural hypoxia using exogenous pyruvate. Their study combined mathematical modelling with metabolic profiling and EPR (electron paramagnetic resonance) imaging. HAP dynamics were modelled using reaction-diffusion/convection equations coupled with fluid-structure interactions. In line with these previous mathematical studies, the aim of this in silico study is to contribute HAP-related insights gained by mathematical modelling, according to a Blackboard-to-Bedside [33] approach.
In clinical settings, the intratumoural oxygenation status can be assessed in multiple ways. By inserting oxygen electrodes into tumours, pO 2 values can directly be measured, but this measuring technique is invasive and does not distinguish between hypoxic and necrotic tumour regions [1] . Alternatively, less invasive imaging techniques, such as positron emission (PETscans) and oxygen-enhanced magnetic resonance (MRIs), can be used to evaluate oxygen levels in tumours [12, 1] . Moreover, there now exist several hypoxia gene expression signatures that may be used to characterise hypoxia-related tumour features, and some of these signatures have been conferred with poor clinical prognoses [1] . Avoiding a tumour biopsy, by measuring hypoxia secreted markers in the blood, would, furthermore, constitute a more expeditious way to assess tumour hypoxia [1] . Without further discussing the advantages and disadvantages of various hypoxia assessment methods, the above discussion illustrates that it is, indeed, feasible to invoke stricter selection regimes when deciding whether or not to pair tumours with HAP treatments in clinical trials [1] . A recent publication, by Spiegelberg et al. [1] , claims that the (lack of) clinical progress with HAP-treatments can, in great part, be attributed to the omission of hypoxia-based patient selection in phase III trials. In this study, we demonstrate that the efficacy of HAP monotherapies and HAP-IR combination therapies in silico is, indeed, highly dependent on tumour-specific oxygen features.
Model
An on-lattice, hybrid, multiscale cellular automaton (CA) is here used to model solid tumours subjected to HAP and IR monotherapies, as well as HAP-IR combination therapies. Tumour growth and HAP responses are parameterised by published data from an in vitro study performed by Voissiere et al. [34] , in which multicellular tumour spheroids (MCTSs) where grown and exposed to HAPs. Specifically, we use their data for human chondrosarcoma HEMC-SS cells exposed to the hypoxia activated prodrug TH-302. Our mathematical model is thereafter extended to simulate in vivo drug dynamics in order to investigate scheduling aspects of HAP-IR combination therapies. The parameters used in this paper can be modified in order to simulate specific cell-lines and drugs, and model rules can be altered in order to simulate both in vitro and in vivo cancer cell populations, MCTSs or tumours. Thus, with the availability of appropriate data, various tumour scenarios and treatment schedules and doses can be investigated in silico. Hence the mathematical model presented here constitutes a valuable and versatile complement to both in vitro and in vivo experiments. The model used in this study is an extension of a previous, well-established model presented by Powathil et al. [35] . All parameters used in the model are motivated from experiments and literature, as described throughout this section, and are summarised in Section 2.7, Table 1 .
Mathematical Framework: A Cellular Automaton (CA)
The CA used in this model allows for spatio-temporal dynamics and intratumoural heterogeneity including variations in cell-cycle progression, oxygen levels, drug concentrations and treatment responses amongst cancer cells [35, 36, 33, 37] . The model is multiscale and integrates both intracellular and extracellular regulations. In vitro experiments have demonstrated that MCTSs are more HAP-sensitive than are monolayers. This increase in sensitivity has been attributed to the microenvironment correlated to multilayer cultures [18] . Aspiring to achieve an in silico model that is as clinically relevant as possible, we here let the CA lattice extend in three spatial dimensions. The lattice is specifically a square lattice containing 100 3 lattice points, simulating a physical environment of (2mm) 3 . Thus each voxel in the lattice spans a volume of (20µm) 3 and each lattice point may be occupied by either one cancer cell or extracellular matrix. These dimensions agree with previous mathematical studies [35] , and cell population density in the MCTSs that are used to calibrate the model [34] . The time step used to model the temporal progression of the CA is ∆t = 10 −4 hours, by appropriate non-dimensionalisation of oxygen dynamics [35] .
Cell-Cycle Progression
On an intracellular scale, sub-cellular mechanisms are modelled individually for each cell in order to allow for variations amongst cancer cells. Cell-cycle progression is one such intracellular process, it is governed by an intrinsic cell-cycle clock attributed to each individual cell. In order to account for cell-cycle asynchronicity amongst cells, each cell i is assigned an individual, stochastic doubling-time τ i which corresponds to the time it takes for a cell to complete one cell-cycle, and double by producing a daughter cell, in well-oxygenated conditions. Here, τ i is picked from a normal distribution [36] with a mean value µ and a standard deviation σ, which are picked to match cell population growth-rates reported from Voissiere et al. [34] . as demonstrated in Figure 1 .
Each cell in the model follows a cell-cycle typical to that of eukaryotic cells. In particular, a cell is defined to be in the gap 1 (G1), synthesis (S), gap 2 (G2) or mitosis (M) phase of the cell-cycle. As sensitivity to radiotherapy is cell-cycle dependent [20] , it is important to track cell-cycle phase progression in the model. Each cell that is placed on the lattice commences its first cell-cycle in the G1 phase. Under well-oxygenated conditions, the fraction of time spent in (1)
The four theta values are picked from literature in order to match typical cell cycle phase lengths of rapidly cycling human cells with a doubling time of roughly 24 hours [38] . Specifically, we set the G1, S, G2 and M phase to respectively occupy 11/24:ths, 8/24:ths, 4/24:ths and 1/24:th of a cell's individual cell-cycle, in terms of time. These values can be amended upon availability of cell-line specific data. Thus the time spent in each of the four distinct cell-cycles, for a well-oxygenated cell i with a cell-cycle length τ i , is here Θ G1 τ i , Θ S τ i , Θ G2 τ i and Θ M τ i for the cell-cycle phases G1, S, G2 and M respectively so that
However, low cellular oxygen levels have been shown to delay cell-cycle progression by inducing arrest in particularly the G1 phase of the cell cycle [39] . Mathematically, the cell-cycle can be modelled in various ways. For example, in mechanistic cell-cycle models derived by Tyson and Novak, the cell-cycle is governed by a regulatory molecular network that can be described by a system of ordinary differential equations [40] . By incorporating hypoxia-induced factors in the system of equations, the G1 phase can be inherently elongated under hypoxic conditions [35] . In this study, however, cell-cycle progression is merely modelled using a phenomenological clock, instead of a more detailed Tyson-Novak type of model. As a result of this, there is no mechanistic functionality driving G1-arrest under hypoxic conditions in our model. To remedy G1 Delay Factor (G1DF) Figure 2 : The G1 Delay Factor (G1DF) is incorporated in the model to achieve oxygendependent G1 arrest. The G1DF (dark line) is extrapolated from in vitro data (red crosses) from a previous mathematical study by Alarcon et al. [39] .
this fact, we here introduce an additional function to achieve an oxygen-dependent length (in units of time) of the G1-phase. We name this function the G1 Delay Factor (G1DF ) such that,
whereK(x, t) denotes the oxygenation (in units of mmHg) of cell in point x at time t. The G1DF, which is illustrated in Figure 2 , is an approximation for how much the G1 phase is expanded in time as a function of oxygen pressure, here measured in units of mmHg. The G1DF is matched to fit data points extracted from a previous mathematical study by Alarcon et al. [39] , in which a Tyson-Novak cell-cycle model is extended to incorporate the action of p27, a protein that is upregulated under hypoxia and delays cell-cycle progression. Thus the time spent in the G 1 phase, τ G1 , is given by
where G1DF (K(x, t)) = 1 for normoxic cells (K(x, t) ≥ 10 mmHg). The lengths of other cell-cycle phases are approximated as non-oxygen dependent in the model.
Tumour Growth
In the model, a tumour is grown from one seeding cancer cell which divides and gives rise to a heterogeneous MCTS. Once a viable, i.e. undamaged, cell has completed the mitosis (M) phase of the cell-cycle, a secondary cell, namely a daughter cell, is produced and placed in the neighbourhood its mother cell. In the model, this cell-division occurs provided that free space is available on the lattice in the νth order neighbourhood of the mother cell, where the value for ν is here fitted form experimental data [34] . This replicates a scenario in which tumour growth may be inhibited by lack of resources such as space or nutrients, as might for example occur in vitro. (By setting ν = ∞, the model can be adapted to disregard these cell-division constraints [36] ). If this is not the case, no daughter cell is produced, and instead the mother cell assumes a state in which they progress through the cell-cycle very slowly (simulating an in vitro spheroid case, in which inner cancer cells experimentally have shown a reduced proliferation rate [34] ), or not at all (simulating an in vivo case in which cells may enter a quiescent G0 phase [35] ). Should neighbourhood space be made available again, as a result of cells getting removed from the lattice due to anticancer treatments, such cells may re-assume an actively cycling state. Each daughter cell is placed on a random lattice point in the neighbourhood of the mother cell, where up to ν spherical neighbourhoods are regarded. In order to agree with the MCTS data [34] used to calibrate the model, we here pick ν = 3, as illustrated in Figure 3 , and thus a daughter cell may be placed up to three neighbourhoods away from its mother cell. To accomplish spherical-like tumour growth the model stochastically alternates between deploying Moore and von Neumann neighbourhoods [35] . In the work presented by this paper, neither necrotic nor apoptotic tumour cells are included in the pre-treatment tumour growth model, and instead we make the simplifying modelling assumption that the density of viable cells is constant (one cancer cell per lattice point) within the simulated MCTSs before any treatment is given. However, CA are easily adaptable and, if appropriate and desired, modelling rules concerning necrotic and/or apoptotic cells can be included in the mathematical framework. The in vitro experiment produced and reported by Voissiere et al. [34] does detect apoptotic cells in the MCTSs, these are primarily located towards the center of the spheroids.
Oxygen Distribution and Hypoxia
Oxygen is assumed to be readily available in the extracellular matrix and, accordingly, extracellular lattice points are oxygen source points. On the other hand, viable (i.e. non-damaged) cells are modelled as oxygen sinks as they consume oxygen in order to function. The distribution of oxygen across the lattice is modelled by a mechanistic partial differential equation (PDE), specifically a reaction-diffusion equation such that
coupled with no-flux boundary conditions. Here K(x, t) denotes the oxygen level in lattice point x at time t. D K (x, t) is the diffusion coefficient, which is higher in lattice points occupied by cells compared to unoccupied lattice points, so that oxygen diffuses slower over cancer cells than in extracellular material in the model [35] . The binary function cell(x, t) is equal to one if the lattice point is occupied by a cancer cell, and zero otherwise. Similarly, the binary function m(x, t) is one if the lattice point is outside the tumour, and zero otherwise. The oxygen production rate is denoted by r K and the cellular oxygen consumption rate is φ K . Thus the first term in the Equation 5 describes oxygen diffusion, the second term describes oxygen production and the final term describes cellular oxygen consumption. In the model, the diffusion coefficient for oxygen is gathered from literature but the production and consumption rates are calibrated in silico to match in vitro data from Voissiere et al. [34] , specifically to achieve appropriate oxygen gradients. Note that the no-flux boundary condition causes the total amount of oxygen on the lattice to increase over time. To express oxygenation levels on the lattice in scaled form, a scaled oxygen variableK(x, t) is introduced which is obtained bŷ
where max n K(n, t) denotes the maximal K(x, t)-value (of all n lattice points) at time t [41] . The scaling-factor, h, (with unit mmHg), is incorporated in order to calibrate the model to fit the MCTS data, as illustrated in Figure 4 . A cell is defined to be hypoxic if it has a scaled oxygen value such thatK(x, t) ≤ 10 mmHg [35] . In the model, theK(x, t)-value influences G1-arrest ( Figure 2 ), radio-sensitivity ( Figure 7 ) and HAP-AHAP bioreduction rates ( Figure  5 ). 
Hypoxia Activated Prodrugs
Anticancer prodrugs constitute relatively harmless compounds in their inactivated form with the potential to bioreduce, or transform, into cytotoxic species [21] . Specifically for HAPs, this bioreduction occurs in hypoxic conditions and thus HAPs are able to selectively target hypoxic tumour regions [21] . The oxygen dependent bioreduction is here modelled by the function
where b is a time-scaling factor with and BRF is a bioreduction factor as illustrated in Figure  5 and
Here [pO 2 ] 50 denotes the oxygen value yielding 50% bioreduction (in one hour), chosen to be 0.2 mmHg, for evofosfamide, as is done in a previous mathematical model by Hong et al. [42] . As illustrated in Figure 5 , the BRF value rapidly decreases for pO 2 values (i.e.K(x, t) values) between 0 and 10 mmHg.
The mechanistic reaction-diffusion equations governing the distribution of HAPs and AHAPs across the lattice are respectively given by [43] are calibrated in silico to make it so that HAPs and IR yield the same effect (in terms of number of cells killed) for a large tumour (see the Large Tumour in Figure 8 ). When a cell dies, it reduces to a membrane-enclosed cell-corpse which is (in vivo) digested by macrophages [44] . In the model, the time it takes for a cell to receive lethal damage until it is removed from the lattice, to give space to other cells, is denoted T L→R (L for lethal, R for removal). Three cases for this time T L→R are investigated in this study: (i) the first extreme case in which a dead cell in never removed from the lattice (simulating an in vitro environment), (ii) the other extreme case in which a cell is instantaneously removed from the lattice upon receiving lethal damage, and (iii) a mid-way case in which a cell is removed from the lattice after a time-period corresponding to its doubling time has passed, i.e. T L→R,i = τ i . Results using the first case are included in the main text, results for cases (ii) and (iii) are provided in the Supplementary Material in which we demonstrate that, within the scope of the performed in silico experiments, this choice of T L→R value does not affect our qualitative findings.
Parameters
In our mathematical model, HAPs are produced on the source points (i.e. extracellular lattice points outside the tumour) and are quickly distributed across the lattice. Drug transportation of HAPs from source points to cells is mediated only by the diffusion terms in Equation 9 and and similarly AHAP transportation is mediated only by the diffusion term in Equation 10 . Consequently, the drug diffusion coefficients D [HAP ] and D [AHAP ] represent all biophysical drug transportation across the lattice in silico. HAPs must possess certain appropriate attributes in order to produce desired effects [18] . Specifically, HAPs should be able to travel relatively long distances without being metabolised, specifically distances longer than that of which oxygen travels, in order to reach hypoxic tumour regions. As oxygen is consumed by the cells, whilst HAPs require certain micro-environmental conditions to be met in order to metabolise, HAPs may reach regions located relatively far away from blood vessels, that oxygen can not reach. It has, indeed, been demonstrated in vivo that TH-302 has the ability to reach hypoxic regions, where it is activated [45] . Conversely, AHAPs should travel relatively short distances in order to localise AHAP activity to tumour regions only, and thus to minimise unwanted extratumoural toxicity. The diffusion length of oxygen is reported in literature to be approximately 100 µm [35] however, to our knowledge, no diffusion length of neither TH-302 nor Br-IPM has been explicitly reported. However, the diffusion length of the HAP/AHAP pair AQ4N/AQ4 has been shown to be reach roughly 1.5 times that of oxygen (or 150µm) in xenografts [46] . With this motivation, we here approximate the diffusion coefficient of TH-302 to be twice that of oxygen. ( According to the relationship L = D/Φ, where L is the diffusion length scale and Φ is the compound uptake, the diffusion coefficient of a certain compound, D, is proportional to L 2 , neglecting details of compound uptake [35] . Thus here we make the simplified approximation that L [HAP ] (x, t) = √ 2 · D K (x, t). ) Similar to previous procedure, the diffusion length of AHAPs is approximated to be half that of oxygen from which it follows that D [AHAP ] (x, t) = (1/4) · D K (x, t). These parameter estimations suffice to conceptually, and qualitatively, describe the nature of HAPs and AHAPs, but can be amended upon the availability of new data. By adjusting the diffusion coefficients D [HAP ] and D [AHAP ] , the influence of bystander effects are allowed to range from negligible to highly influential in our mathematical framework.
The half-life times of TH-302 and Br-IPM have been reported to be 0.81h and 0.70h respectively in a clinical trial [11] , these values are used to determine the decay rates η [HAP ] and η [AHAP ] . This half-life time of TH-302 is in accordance with preclinical predictions obtained from allometric scaling [26] . Note that the drug decay coefficients, η [HAP ] and η [AHAP ] in Equation 9 and Equation 10 respectively, simulate all drug clearance from the system, i.e. both metabolic clearance and excretion.
Radiotherapy
Cellular responses to radiotherapy are dependent on oxygenation status [4] , cell-cycle phase [47, 48] , and cell-line characteristics. Cellular radiotherapy responses are here modelled using an appropriate CA adaptation of the widely accepted Linear-Quadratic (LQ) model. In the traditional LQ model, the survival fraction of a cell population is given by S(d) = e −nd(α+βd) , where d is the radiation dosage, n is the number of administered radiation fractions and α and β are cell-line specific sensitivity parameters [49] . To include cell-cycle sensitivity, α and β are here cell-cycle dependent and the oxygen modification factor (OMF) is incorporated to include oxygen sensitivity [50] , such that OMF = OER(K(x, t)) OER m 
Oxyen Enhancement Ratio (OER) and Oxyen Modification Factor (OMF)
OER OMF Figure 6 : The Oxygen Enhancement Ratio (OER) and the Oxygen Modification Factor (OMF) are incorporated in the mathematical model to quantify the influence of oxygen on radiotherapy responses. Cells are the most least radiosensitive for low pO 2 values. The OER and OMF curves have steep gradients between the oxygen values 0 and 10 mmHg, after which they respectively asymptote to the values 3 and 1 for higher oxygen values.
where
where OER m = 3 is the maximum value under well-oxygenated conditions and K m = 3 mmHg is the pO 2 value achieving half maximum ratio [41] . The OER and OMF functions are illustrated in Figure 6 .
The survival probability of a cell in point x at time t is here given by
where the cell-cycle phase specific α and β values are gathered from a previous study by Kempf et al. [51] , and are listed in Table 1 . Cellular responses to a 2Gy IR dose for a generic cancer cell-line, as a function of oxygenation and cell-cycle phase details, are illustrated in Figure  7 . Figure 7 : The probability that a cell, in the mathematical model, exposed to a radiotherapy dose of 2 Gy survives. The survival probability S(x, t) is function of its cell-cycle phase and oxygenation value. Cells are the least radiosensitive when hypoxic. Table 1 : A summary of model parameters used in the mathematical framework.
Parameters
In this study we attempt to replicate the nature of generic eukaryotic cell-lines, the HAP evofosfamide (TH-302) and its corresponding AHAP, Br-IPM. The parameters, which are listed in Table 1 , are chosen accordingly but can be adapted to represent other specific cell-lines or drugs upon data becoming readily available.
Implementation and in silico Framework
The mathematical model is implemented in an in-house computational framework written in C++ deploying high-performance computing techniques. The PDEs describing oxygen and drug distribution across the lattice are solved using explicit finite difference methods with noflux boundary conditions. Maps of cancer cells and the microenvironment are visualised in ParaView [52] . Using this computational framework, various experimental in vitro and in vivo scenarios are formulated and simulated in silico. In order to grow an in silico MCTS, one seeding cancer cell is placed on the lattice and this cell divides and gives rise to a MCTS that is heterogeneous in nature, as in-built model stochasticity creates cell-cycle asyncronosity amongst tumour cells [53] , and oxygen levels vary across the MCTS. Such virtual spheroids are thereafter subjected to various treatment combinations comprising HAPs and IR. Treatment commence when MCTSs consist of, in the order of, 100,000 cancer cells or 'agents' in our agent-based model. Due to the high number of agents, and the fact that the intrinsic model stochasticity only involves a few events during the simulated treatment time (specifically 0-3 cell divisions and potentially one response to radiotherapy) the quantitative results do not differ much between in silico runs. Performing the same in silico experiment 10 times yields a standard deviation that can be regarded as negligible (less than 0.5%), and thus we argue that basing our results from means from 10 simulation runs per experiment is enough to mitigate intrinsic model stochasticity to a level that is sufficient for this qualitative study.
Results and Discussion
In Sections 3.1 through to 3.3, we compare treatment responses in two different in silico tumour spheroids, specifically a 'Large' and more hypoxic MCTS and a 'Small', less hypoxic MCTS. The 'Small' tumour corresponds to the 20 day-old MCTS in Figures 3 and 4 , that is calibrated by in vitro data from Voissiere et al. [34] . The 'Large' MCTS is extrapolated by letting the 'Small' MCTS grow for yet another 10 days in silico, until it reaches an age of 30 days. The 'Small' and 'Large' MCTSs are illustrated in Figure 8 .
The simulated IR dose is chosen to be 2 Gy, and to allow for intuitive comparisons between the two different monotherapies, the HAP dose (Dose HAP ) is here qualitatively chosen, and calibrated to yield the a similar in silico response as the 2 Gy IR dose (in terms of cell survival) in the 'Large' MCTS. Quantitative doses can be specified and implemented upon the availability of data.
HAP and IR monotherapies attack tumours in different ways
In this initial in silico experiment, a MCTS is subjected to a monotherapy of either one dose of HAPs or one dose of IR. Our in silico results demonstrate that HAP and IR monotherapies attack the MCTS in different ways. This can be understood by regarding the treatment responses in Figure 9 and Figure 10 . Figure 9 shows cell-cycle phase specific survival data, in terms of cell count over time, when the 'Small' or 'Large' MCTS is subjected to a HAP or IR monotherapy. Similarly, Figure 10 shows the composition of cells, in terms of their cell-cycle phase, in response to a HAP or IR monotherapy dose. Our results demonstrate that for the 'Small', well-oxygenated MCTS, HAPs have negligible effect on the cell count (see Figure 9 ) and, by extension, on the cell-cycle phase composition (see Figure 10 ). This shows that, by design, HAP treatments have little effect on tumours that are not hypoxic enough to cause significant HAP-to-AHAP bioreduction. For the 'Large' MCTS, however, HAPs successfully eliminate cells, particularly the inner cells of the MCTS, labeled 'Slow/non-proliferative' (see Figure 9 ). This causes an alteration in the cell-cycle phase composition in favour of the proliferative cells in the outer shell of the MCTS (see Figure 10 ). Our results further show that, for both the 'Small' and the 'Large' MCTSs, IR eliminates cells of all cell-cycle states (see Figure  9 ), but alters the cell-cycle phase composition in favour of the inner, hypoxic cells as these are less sensitive to radiotherapy (see Figure 10 ). These opposing effects on the cell-cycle phase composition achieved by HAPs and IR in the 'Large' MCTS indicate that, for tumours that are hypoxic enough for HAPs to have an effect, HAP-IR combination treatments have the potential of producing multifaceted attacks on tumours.
Since radiation responses are enhanced by the presence of molecular oxygen, we investigated which monotherapy (i.e. HAP or IR) best eliminates hypoxic cells and reoxygenates MCTSs after one single treatment dose. To demonstrate the overall alteration of oxygenation levels in the MCTSs as a result of the monotherapies, Figure 11 provides histograms for cellular oxygenation levels at time T 0 (the time of therapy administration) and at time T 0 + 4 hours. From this figure we can see that for the 'Small' MCTS, HAPs do not alter the overall intra-tumoural oxygenation but IR does, since HAPs are not efferctive but IR is. For the 'Large' MCTS, on the other hand, both HAPs and IR alter the overall intra-tumoural oxygenation but only HAPs manage to eliminate the most hypoxic cells, and thus shift the oxygen histogram away from the most severe levels of hypoxia. This indicates that administering HAPs as a neoadjuvant therapy prior to radiotherapy may enhance the effect of radiotherapy in tumours that are sufficiently hypoxic for HAPs to be effective. Cell count 10 4 Small MCTS 
HAP-IR treatment scheduling impacts HAP efficacy in sufficiently hypoxic tumours
In order to study the optimal treatment scheduling of HAP-IR combination therapies, simulated MCTSs are here given one dose of HAPs and one dose of IR, using different schedules. Figure  12 shows the cell count over time when one dose of HAPs and one dose of IR are administered with various schedules. Specifically, either HAPs is given at 0 hours (followed by IR at 0, 12, 24 or 48 hours) or IR is given at 0 hours (followed by HAPs at 0, 12, 24 or 48 hours). The results in Figure 12 demonstrate that for the 'Small' MCTS, scheduling does not impact the overall treatment outcome, as HAPs are not effective. For the 'Large' MCTS however, it is more effective to give HAPs before IR, than to give IR before HAPs. This indicates that, in tumours that are hypoxic enough for HAPs to be effective, the HAP-IR treatment scheduling impacts the efficacy of the combination treatment.
HAPs enhance radiotherapy effects in sufficiently hypoxic tumours
To investigate if and when HAPs enhance the effect of radiotherapy, simulated MCTSs are subjected to either IR monotherapies or HAP-IR combination therapies. In the combination therapy case, HAPs are administered at time T 0 and IR is administered at time T 0 + 48 hours. In the monotherapy case, radiotherapy is administered at time T 0 + 48 hours. For a thorough investigation, the oxygen-levels of the 'Large' and 'Small' tumours are further scaled by multiplication with a factor 1, 1/2 or 1/4 so that we have 6 different tumours on which to test if neoadjuvant HAPs enhances radiotherapy efficacy. Figure 13 shows IR treatment responses in form of survival data (both in terms of number of surviving cells and fraction of surviving cells). From these plots we see that for very hypoxic MCTSs, the administration of neoadjuvant HAPs does increase the effect of radiotherapy. However, for well-oxygenated MCTS, neoadjuvant HAPs do not increase the effect of radiotherapy. Figure 14 . The severely hypoxic cancer cells are here called activator cells, as the prodrug bioreduction (or activation) is maximal in severly hypoxic environments. The well-oxygenated cells are here referred to as bystander cells, as the bioreduction is minimal in well-oxygenated environments. Thus any lethal AHAP concentration occurring in a bystander cell is a result of HAP-to-AHAP bioreduction occurring outside the bystander cells. From Figure 15 it is clear that the bystander effects are higher in MCTS B than in MCTS A, although all activator cells are eliminated in both MCTSs. When the activator cells are spread out across the spheroid, as in MCTS B, there are more interfaces in which bystander cells experience significant bystander effects. Although the oxygen landscape in MCTS B is highly synthetic, this in silico experiment shows that the intratumoural oxygen landscape impacts the efficacy of HAPs. 
The intratumoural oxygen landscape impacts HAP efficacy

Conclusion
Previous in vitro and in vivo studies have validated the successfulness of HAPs in laboratory settings, however, this preclinical success has not yet been reflected in clinical trials. In an attempt to elucidate the unsatisfactory results from clinical HAP trials, we in this study investigate how oxygen-related tumour features and treatment administration plans impact the efficacy of HAP monotherapies and HAP-IR combination therapies in silico. To this end we have developed a mathematical model capturing the spatio-temporal dynamics of tumours subjected to multimodality treatments comprising HAPs and IR. A set of results (i to iv) relating to HAP efficacy in silico have here been demonstrated.
i HAPs and IR attack tumours in different, complementary, fashions. Whilst IR provides a highly effective way to kill cancer cells in tumours, hypoxic and resting cells are significantly more resistant to IR than are well-oxygenated and actively cycling cells. HAPs, however, are alkylating agents which bioreduce in (primarily) hypoxic areas, hence HAPs primarily inflict damage in hypoxic tumour regions, which are especially susceptible to HAP damage. Consequently, HAP-IR combination treatments have the potential of produce a multifaceted attack on tumours.
ii In sufficiently hypoxic tumours, the HAP-IR treatment schedule influences treatment efficacy. However, in well oxygenated tumours the schedule is not important.
iii In sufficiently hypoxic tumours, HAP functions as a treatment intensifier, however, in well oxygenated tumours it does not.
iv Not only the overall intra-tumoural oxygenation levels, but also the intratumoural oxygen landscape, impacts HAP efficacy.
In a recent publication, Spiegelberg et al. [1] , claim that the (lack of) clinical progress with HAP-treatments can, in great part, be attributed to the omission of hypoxia-based patient selection. This in silico demonstrates that whilst HAPs are effective treatment intensifiers for sufficiently hypoxic tumours, they have negligible effect on more well-oxygenated tumours. In simple terms: some tumours are suitable to be paired with treatment plans involving HAPs whilst others are not. In line with Spiegelberg et al.'s claims [1] , our in silico results indicate that a personalised medicine approach is preferable if treatments involving HAPs (that are similar to TH-302) are to achieve their maximum potential in clinical settings. In this study, we qualitatively studies various aspects of HAP-IR treatment schedules using a multiscale mathematical framework. Upon the availability of in vitro and in vivo data, this mathematical framework can be calibrated in order to serve as an in silico testbed for predicting HAP-IR treatment scenarios. As a result of interdisciplinary collaborations, the mathematical framework used in this study has previously been validated in vitro and in vivo for applications other than HAP-IR combination treatments [54, 36] . The multiscale nature of the framework enables integration of data from various scales, be it from the subcellular scale, the cellular scale or the tissue scale. As an example of useful data, the multi cellular tumour spheroid data previously produced by Voissiere et al. [34] provided our framework with calibration data for tumour growth and spatio-temporal oxygen dynamics. Using existing experimental data to create data-driven mathematical models is a resourceful step involved in the advancement of mathematical oncology [55] . Figure 12 , are qualitatively the same if a damaged cell is instantly removed from the lattice (Figure 16) or if a damaged cell is moved from the lattice after a time period corresponding to its doubling time ( Figure 17 ). Cell count 10 4 Small MCTS 19 show that the experiment that investigates if HAPs act as radiotherapy enhancers, discussed in Section 3.3 and with results provided in Figure 13 , are qualitatively the same if a damaged cell is instantly removed from the lattice (Figure 18) or if a damaged cell is moved from the lattice after a time period corresponding to its doubling time ( Figure 19 ). Figure 19 : Treatment responses of radiotherapy in various MCTSs when either (1) an IR monotherapy dose is administered at T 0 +48 hours or (2) IR is given at T 0 +48 hours following a prior HAP dose at time T 0 . Complement to Figure 13 . Cells are removed from the lattice after a time corresponding to their doubling time (τ i ) post the lethal event occurred.
